The Technology Tree of Xueba

Xinghuo Biological Co., Ltd. finally built a factory after a surprise construction.

On December 2, Zhou Yu visited a factory not far from the company headquarters.

Wang Jian led Zhou Yu to visit the factory and introduced the current situation of the products at the same time.

Director Wang Xiaoxiao led the scientific researchers of the Life Science Research Institute to cooperate with major medical institutions in Yanjing to conduct clinical trials of three products.

After the documentary-style advertisement was broadcast, many critically ill patients applied for clinical trials.

Their participation has improved the data of many diseases, making the progress of clinical trials very fast, and the competent authorities have also sent experts to watch the data of clinical trials.

Due to the great pressure from the society, many celebrities and veteran cadres wrote letters to the competent authorities, asking them to quickly review products such as cell missiles.

After the competent authorities have confirmed the safety and real effect of our products, they have reviewed and approved the drugs we declared, and the drug approval numbers have been issued, and they can be officially launched for sale.

Things are progressing very well. Let's take a look at the situation of the factory first. The normal production and storage of medicines are sufficient, and the market will start.

I have told Xinghuo Smart Company that they have trained artificial intelligence masters, and there will be artificial intelligence masters to guide doctors to use medicines. Zhou Yu said happily.

He knew that after these three medicines came into the market, they would definitely be targeted by domestic and foreign pharmaceutical groups, but these three medicines were all medicines that benefited the country and the people.

According to expert estimates, they can at least increase China's average life expectancy by 5 years and reduce the mortality rate of children under the age of ten by 95%.

At the same time, it surpassed artificial intelligence and software games to become the most profitable project of Spark Technology.

For the benefit and reputation of Spark Technology, they are not afraid of any challenges now.

As long as there is no ability to erase Spark Technology from the earth, business wars and other battles, the size of Spark Technology is now nothing to fear.

Wang Jian led Zhou Yu into the factory, where there were huge glass jars.

The glass jar is strictly sealed, the product is completely kept in a sterile state, a holographic image is displayed on the glass jar, and there are many sensors to monitor every data of the product.

Zhou Yu had long learned about the production process of medicines from Director Wang Xiaoxiao.

In addition to disease-screening agents, the other two agents were inspired by the study of hematopoietic stem cells.

The production of these three medicines is also inseparable from cell culture technology, and this place is actually a veritable cell factory.

Zhou Yu and Wang Jian walked to the production workshop, in front of the equipment consisting of thousands of small jars, which are the production equipment for disease screening drugs.

Zhou Yu immediately remembered the process of producing disease screening drugs.

Disease screening agents are a set of complex peptide solutions, and more than 1,000 peptides are mixed together to form disease screening agents.

Each polypeptide can and can only react with a pheromone in human plasma, and the result of the reaction is the folding of the polypeptide chain to form a fluorescent protein.

Just test the type of fluorescent protein in the reagent. The diseases suffered by the sample provider can be read out.

Each polypeptide is expressed by a small piece of gene fragment constructed through modern genetic technology, and the gene fragment is transplanted into a yeast cell screened in the laboratory.

During the proliferation of yeast cells, a large amount of polypeptide substances will be produced.

When all the peptides are mixed together, they become disease screening agents.

Wang Jian introduced to Zhou Yu: Disease screening agent is a polypeptide solvent. Its best storage temperature is around zero degrees. Once the temperature exceeds 40 degrees, the polypeptide chain will automatically dehydrate and condense, losing the effect of detecting diseases.

Each disease screening agent is made into a reagent bottle the size of a pinky finger and transported to medical institutions by special vehicles.

Instruments that use disease screening agents have been handed over to Xinghuo Precision Manufacturing Company for production, and they have a lot of orders.

Zhou Yu and Wang Jian walked to the production workshop on the left again. There are many glass jars filled with red liquid and light yellow liquid. At first glance, it is the production equipment of blood cells and plasma.

The technology of plasma production is very simple. Water accounts for about 92%, most of which are plasma proteins, and contain a small amount of nutrients, electrolytes, enzymes, hormones, etc.

It is easy to synthesize plasma as long as you master the best proportioning ratio.

The real difficulty is the production of blood cells, especially platelets and red blood cells, which are functional cells that play a decisive role in the blood, and it is necessary to make the industrially produced cells cellularly viable.

Director Wang Xiaoxiao cultivated hematopoietic stem cells similar to cancer cells through gene modification technology.

The genetically modified blood stem cells are completely different from cancer cells.

Cancer cells have the ability to proliferate indefinitely, but they have lost their ability to differentiate.

Genetically modified hematopoietic stem cells have the unlimited proliferation ability of cancer cells, but they still maintain the ability to differentiate functional cells.

When hematopoietic stem cells are cultured in nutrients, they have the ability to proliferate indefinitely and can rapidly reproduce themselves.

Once induced with chemical reagents, this hematopoietic stem cell will differentiate into corresponding blood cells, mainly red blood cells, white blood cells and platelets.

Pointing to these tanks, Wang Jian introduced: This is the artificial blood produced by our company, and now we can produce 10 tons of artificial blood every day.

We encapsulate various types of blood, and our company has its own transportation fleet to transport finished blood by professional vehicles.

We also cooperate with the Railway Corporation to transport blood with the help of the high-speed rail backbone network by mounting special high-speed rail carriages.

When Zhou Yu heard Wang Jian's introduction, he was a little surprised. The method of cooperation with the Railway Corporation was completely negotiated by Wang Jian on his own ability.

This method is really good. The fastest way is air transportation, but the transportation of artificial blood requires high requirements, and the aircraft needs to be modified, so the transportation cost is too high.

The rest is transported by high-speed rail, and the cost of transforming a carriage can be borne by Xinghuo Biological Company, but the most important problem is to open up the channel of the railway company.

You have done a great job on this matter. If it is really emergency blood, you can send people to carry it by air on a small scale. The factory-style transportation method and the high-speed rail network are really a good choice. Zhou Yu praised.

They finally came to the production workshop of cell missiles, where there are also tall giant jars.

The cell missile production technology is similar to that of hematopoietic stem cells. It first stimulates lymphatic B cells with antigens, allowing them to produce plasma cells that can produce specific antibodies.

Afterwards, through genetic modification technology, the plasma cells have the ability to proliferate indefinitely, and at the same time, the ability to generate antibodies is changed by modifying the gene.

In this way, the genetically modified plasma cells are placed in the culture medium, and it can continuously produce the same antibodies.

Wang Jian said: The cell missile is a mature protein antibody, which adapts very well to ultra-low temperatures and can withstand high temperatures of about 50 degrees.

It only needs to change the packaging material, and it can be transported at room temperature.

Zhou Yu looked at the huge cell factory that operated autonomously without anyone.

He said with emotion: It is this small cell factory that will rewrite the trajectory of human medical development.